Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Splenic Marginal Zone Lymphoma

被引:6
|
作者
Albano, Domenico [1 ,2 ]
Camoni, Luca [2 ]
Giubbini, Raffaele [1 ,2 ]
Bertagna, Francesco [1 ,2 ]
机构
[1] Univ Brescia, Nucl Med, Brescia, Italy
[2] Spedali Civili Brescia, Nucl Med, Ple Spedali Civili 1, I-25123 Brescia, Italy
来源
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷 / 11期
关键词
MTV; Prognosis; SMZL; Splenic marginal zone lymphoma; TLG; TUMOR VOLUME; 18F-FDG PET/CT; MALT LYMPHOMA; TOMOGRAPHY; GUIDELINES; CONSENSUS;
D O I
10.1016/j.clml.2020.06.018
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study investigated the potential value of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography metabolic features in estimating progression-free survival (PFS) and overall survival (OS) in patients affected by splenic marginal zone lymphoma. The estimated 2-year PFS and OS rates were 78% and 90%, whereas 5-year PFS and OS rates were 63% and 82%. Only lesion to liver maximum standardized uptake value ratio and lesion to blood-pool maximum standardized uptake value ratio were independent prognostic factors for PFS. By contrast, for OS, no positron emission tomography/computed tomography features were correlated with outcome. Introduction: Splenic marginal zone lymphoma (SMZL) is an indolent non-Hodgkin lymphoma usually with a good prognosis, but no clear metabolic behavior at fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ( F-18-FDG PET/CT). The aim of our analysis was to investigate the prognostic role of baseline F-18-FDG PET/CT parameters in SMZL. Materials and Methods: We retrospectively included 42 patients who received F-18-FDG-PET/CT before any treatments, and PET images were evaluated visually and semi-quantitatively by measuring lesion to liver (L-L) maximum standardized uptake volume (SUVmax) ratio (L-L SUV R), lesion to blood-pool SUVmax ratio ( L-BP SUV R), metabolic tumor volume, and total lesion glycolysis. Progression-free (PFS) and overall survival (OS) curves were plotted according to the Kaplan-Meier method. Results: In all patients, an increased splenic FDG uptake (higher than the background) was identified, showing the presence of diffuse spleen uptake in 35 patients and focal uptake in the remaining 7 patients. At a median follow-up of 51 months, relapse or progression of disease occurred in 23 patients with an average time of 38.1 months from the baseline F-18-FDG PET/CT, and death occurred in 4 patients with an average time of 26.8 months. The estimated 2-year PFS and OS rates were 78% and 90%, respectively, whereas 5-year PFS and OS rates were 63% and 82%, respectively. At multivariate analysis, only L-L SUV R and L-BP SUV R were independent prognostic factors for PFS. In addition, no significant association was discovered for OS, considering all features. Conclusions: L-L SUV R and L-BP SUV R were independently correlated with PFS. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:E897 / E904
页数:8
相关论文
共 50 条
  • [21] Prognostic value of 18F-FDG PET/CT-based metabolic parameters in patients with bone sarcoma
    Garcia Belaustegui, L.
    Wakfie Corieh, C.
    Valhondo Rama, R.
    Blanes Garcia, A.
    Cabrera Martin, M.
    Carreras Delgado, J.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S509 - S509
  • [22] Prognostic Value of Intratumor Metabolic Heterogeneity Parameters on 18F-FDG PET/CT for Patients with Colorectal Cancer
    Liu, Xin
    Xiang, Kun
    Geng, Guang-Yong
    Wang, Shi-Cun
    Ni, Ming
    Zhang, Yi-Fan
    Pan, Hai-Feng
    Lv, Wei-Fu
    [J]. CONTRAST MEDIA & MOLECULAR IMAGING, 2022, 2022
  • [23] Prognostic value of metabolic parameters determined by preoperative 18F-FDG PET/CT in patients with uterine carcinosarcoma
    Lee, Hyun Ju
    Lee, Jong Jin
    Park, Jeong-Yeol
    Kim, Jong-Hyeok
    Kim, Yong-Man
    Kim, Young-Tak
    Nam, Joo-Hyun
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (04)
  • [24] Prognostic Value of Textural Features of Pretreatment 18F-FDG PET/CT in Patients with Lymphoma
    Kote, Rutuja
    Ravina, Mudalsha
    Nanda, Siddhartha
    Kashyap, Yashwant
    Kumar, Amit
    Lukose, Tinu
    Moideen, Amal
    Bansal, Himanshu
    Krishna, Sarin
    Dasgupta, Subhajit
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2022, 63
  • [25] 18F-FDG PET/CT for primary staging of patients with testicular germ cell tumors: the predictors of 18F-FDG PET positivity and prognostic value of PET derived metabolic parameters
    Aydos, Uguray
    Tahtaci, Gozde
    Ozgur Akdemir, Umit
    Ozet, Ahmet
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2020, 41 (11) : 1199 - 1209
  • [26] The Value of Interim 18F-FDG PET/CT in Hodgkin lymphoma
    Molnar, Z.
    Deak, B.
    Kajary, K.
    Lengyel, Z.
    Molnar, P.
    Rosta, A.
    Schneider, T.
    Szaleczky, E.
    Varga, F.
    Varady, E.
    Borbely, K.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S165 - S165
  • [27] Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma
    Peng Xie
    Jin-Bo Yue
    Han-xi Zhao
    Xin-Dong Sun
    Li Kong
    Zheng Fu
    Jin-Ming Yu
    [J]. Journal of Cancer Research and Clinical Oncology, 2010, 136 : 883 - 889
  • [28] Prognostic Value of 18F-FDG PET/CT-Metabolic Parameters at Baseline and Interim Assessment in Pediatric Anaplastic Large Cell Lymphoma
    Mathew, Boon
    Vijayasekharan, Kalasekhar
    Shah, Sneha
    Purandare, Nilendu C.
    Agrawal, Archi
    Puranik, Ameya
    Prasad, Maya
    Narula, Gaurav
    Banavali, Shripad
    Rangarajan, Venkatesh
    [J]. CLINICAL NUCLEAR MEDICINE, 2020, 45 (03) : 182 - 186
  • [29] The prognostic value of quantitative parameters of 18F-FDG PET/CT imaging for extranodal NK/T cell lymphoma
    Yuan, T.
    Zhang, Y.
    Wei, M.
    Chen, X.
    Lin, X.
    Wang, X.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S212 - S213
  • [30] Prognostic value of pretreatment 18F-FDG PET/CT in Neuroblastoma
    Sung, Andrew
    Trout, Andrew
    Zhang, Bin
    Weiss, Brian
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61